ALDX - Aldeyra gains as Oppenheimer upgrades on revised plans for lead asset
2024-04-03 09:01:58 ET
More on Aldeyra Therapeutics
- Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie
- Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects
- Aldeyra gains on plans for AbbVie-partnered eye disease drug
- Seeking Alpha’s Quant Rating on Aldeyra Therapeutics
- Historical earnings data for Aldeyra Therapeutics